FDA approval for Lupin’s Nikita (Pitavastatin) tablets
09 August 2017 | News
These tablets are Pitavastatin Sodium which is an alternate salt product of Kowa Company Ltd’s Livalo (Pitavastatin Calcium) Tablets
Source: Pixabay
Pharma company Lupin Limited has announced that it has received a 505 (b) (2) NDA approval for its NikitaTM (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA).
These tablets are Pitavastatin Sodium which is an alternate salt product of Kowa Company Ltd’s Livalo (Pitavastatin Calcium) Tablets.
It is a new option for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase high-density lipoprotein cholesterol.
